VTV THERAPEUTICS

vtv-therapeutics-logo

vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. vTv Therapeutics has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, in... flammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company. The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology. vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo. Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification. vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.

#SimilarOrganizations #People #Financial #Event #Website #More

VTV THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Innovation Management Pharmaceutical

Founded:
1998-01-01

Address:
High Point, North Carolina, United States

Country:
United States

Website Url:
http://www.vtvtherapeutics.com

Total Employee:
251+

Status:
Active

Contact:
+3368410300100

Email Addresses:
[email protected]

Total Funding:
41 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress


Similar Organizations

idera-pharmaceuticals-logo

Idera Pharmaceuticals

Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.

sorrento-therapeutics-logo

Sorrento Therapeutics

Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.


Current Advisors List

jonathan-isaacsohn_image

Jonathan Isaacsohn Board Member @ vTv Therapeutics
Board_member

rich-nelson_image

Rich Nelson Board Member @ vTv Therapeutics
Board_member
2020-11-01

Current Employees Featured

not_available_image

Imogene Dunn
Imogene Dunn SVP, BioMetrics and Regulatory @ vTv Therapeutics
SVP, BioMetrics and Regulatory

rich-nelson_image

Rich Nelson
Rich Nelson Interim CEO @ vTv Therapeutics
Interim CEO
2022-03-03

jeffrey-b-kindler_image

Jeffrey B. Kindler
Jeffrey B. Kindler Executive Chairman @ vTv Therapeutics
Executive Chairman
2015-01-01

carmen-valcarce_image

Carmen Valcarce
Carmen Valcarce SVP, Chief Scientific Officer @ vTv Therapeutics
SVP, Chief Scientific Officer

paul-sekhri_image

Paul Sekhri
Paul Sekhri CEO & President @ vTv Therapeutics
CEO & President
2022-07-01

robert-c-andrews_image

Robert C. Andrews
Robert C. Andrews Sr Vice President, Chemistry, Pharmaceutical Development, and Quality @ vTv Therapeutics
Sr Vice President, Chemistry, Pharmaceutical Development, and Quality
2015-05-01

Stock Details


Company's stock symbol is NASDAQ:VTVT

Investors List

cinpax_image

CinPax

CinPax investment in Post-IPO Equity - vTv Therapeutics

g42-healthcare_image

G42 Healthcare

G42 Healthcare investment in Post-IPO Equity - vTv Therapeutics

Official Site Inspections

http://www.vtvtherapeutics.com Semrush global rank: 3.4 M Semrush visits lastest month: 4.6 K

  • Host name: cloudhost-1964024.us-midwest-1.nxcli.net
  • IP address: 104.207.254.13
  • Location: Southfield United States
  • Latitude: 42.4593
  • Longitude: -83.2207
  • Metro Code: 505
  • Timezone: America/Detroit
  • Postal: 48075

Loading ...

More informations about "vTv Therapeutics" on Search Engine